For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Researchers have found that polyphenols cause the secretion of hormones that may help lower a risk of developing type 2 ...

More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...

In 2024, a plethora of novel therapeutic strategies for kidney disease progressed to clinical trials, including an RNA interference therapeutic, a glucagon-like peptide 1 receptor agonist ...

Weight loss tops many folks' list of New Year's resolutions, and lots of people are turning to cutting-edge weight-loss drugs ...

These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose ...

Artificial intelligence's potential in ophthalmology, particularly in ocular imaging, was a major focus, with debates on its ...